Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 1, 2000, Pages 15-20

  Middleton, Mark R ^a,b   Kelly, Jane ^b   Goodger, Sarah ^b   Thatcher, Nicholas ^a,b   Margison, Geoffrey P ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alkyltransferase; Melanoma; Schedule; Temozolomide; Xenograft

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DOSE TIME EFFECT RELATION; ENZYME DEFICIENCY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0033968973     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006737     Document Type: Article

References (20)

1. 1. Blechen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin G, Brampton MH, Stevens MFG (1995) Cancer Research Campaign Phase II Trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910
2. 2. Stevens MFG, Hickman J, Langdon S, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson N, Slack J, Newton C, Lunt E, Fizames C, Lavelle F (1987) Antitumor activity and pharmacokinetics in mice of 8 carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846
3. 6-methylguanine as a free base. Cancer Res 46: 1663
4. 6-alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 15: 279
5. 5. Margison GP, O'Connor PJ (1990) Biological consequences of reactions with DNA: role of specific lesions. In: Cooper C, Grover P (eds) Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, p 547
6. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119
7. 7. Jelinek J, Kleibl K, Dexter TM, Margison GP (1988) Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents. Carcinogenesis 9: 81
8. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69: 452
9. 6-alkylguanine-DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer (abstract). Proc Am Soc Clin Oncol 16: A366
10. 10. Newlands ES, Blackledge G, Slack J, Rustin G, Smith D, Stuart N, Quarterman C, Hoffman R, Stevens MFG, Brampton MH, Gibson A (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287
11. 6-methylguanine. Cancer Res 49: 6997
12. 12. Micetich K, Futscher B, Koch D, Fisher R, Erickson LC (1992) Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst 84: 256
13. 13. Lee SM, Margison GP, Woodcock A, Thatcher N (1993) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 67: 1356
14. 14. Gibson NW, Hartley JA, Barnes D, Erickson LC (1986) Combined effects of streptozotocin and mitozolomide against four human cell lines of the Mer+ phenotype. Cancer Res 46: 4995
15. 15. Futscher B, Micetich K, Barnes D, Fisher R, Erickson LC (1989) Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun 1: 65
16. 6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89: 1566
17. 17. Friedman H, Dolan ME, Moschel R, Pegg AE, Felker G, Rich J, Bigner D, Schold J (1992) Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 84: 1926
18. 6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40: 266
19. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3: 837
20. 6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 381: 227